UK Markets closed

Sanofi (SNY)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
44.38+0.96 (+2.20%)
As of 03:56PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close43.42
Open43.97
Bid44.45 x 900
Ask44.46 x 800
Day's range43.73 - 44.59
52-week range41.91 - 58.10
Volume4,574,299
Avg. volume2,599,632
Market cap111.538B
Beta (5Y monthly)0.36
PE ratio (TTM)15.92
EPS (TTM)2.79
Earnings dateN/A
Forward dividend & yield1.75 (3.51%)
Ex-dividend date26 May 2022
1y target est69.00
  • Zacks

    Pharma Stock Roundup: PFE to Buy GBT, JNJ to Stall Baby Talc Sale Globally From 2023

    Pfizer (PFE) offers to buy Global Blood Therapeutics (GBT) for $5.4 billion in cash. J&J (JNJ) to discontinue selling talc-based baby powder globally from 2023.

  • Motley Fool

    2 Top Biotech Stocks to Buy Right Now

    Merck (NYSE: MRK) is best known for the top-selling cancer drug in the world, Keytruda, which has produced a staggering $10.1 billion in sales through the first half of this year. Keytruda comprised only 33% of the drugmaker's $30.5 billion in total first-half sales. Merck has a pipeline of more than 100 projects under clinical development, which should give it enough firepower to grow revenue and profits with new product launches.

  • Reuters

    Drugmakers' shares stabilise after Zantac litigation slump

    Shares in GSK, Sanofi, Haleon and Pfizer began to recover on Friday after the companies said that nothing material had changed regarding U.S. litigation focused on heartburn drug Zantac. The companies' share prices had fallen sharply this week on investor concern about the litigation over potential cancer-causing impurities that prompted the drug's withdrawal from markets in 2019 and 2020. Among other disclosures, recently listed Haleon had highlighted the risk of such lawsuits in its prospectus.